Real-time spectroscopic photoacoustic/ultrasound (PAUS) scanner withsimultaneous fluence and motion compensation to guide and validateinterventions: system development and preclinical testing.

实时光谱光声/超声 (PAUS) 扫描仪，具有同步注量和运动补偿功能，可指导和验证干预措施：系统开发和临床前测试。

基本信息

批准号：
10672299
负责人：
Matthew O'Donnell
金额：
$ 73.27万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-22 至 2025-06-30
项目状态：
未结题

项目摘要

Abstract The goal of this project is to develop a clinical real-time spectroscopic photoacoustic/ultrasound (PAUS) system for molecular guidance of interventional procedures through a partnership between UW and GE Research. Recently, we proposed a new, fast-sweep concept for PA imaging. To put this concept into practice, we first developed a unique, compact, diode-pumped, tunable (700 -900 nm) laser operating at very high (up to 1000 Hz) repetition rates and relatively low (~ 1 mJ) pulse energies, and a fiber-optic delivery system to sequentially couple laser pulses into the imaging probe. In addition to US B-mode, and all other US modes, the system simultaneously produces real-time (50 Hz) spectroscopic PA images, which were combined for the first time for real-time PAUS imaging. A unique feature is automatic on-line laser-fluence compensation and motion correction, enabling quantitative optical absorption spectroscopy at every image pixel. Spectroscopy can identify substances opaque to US based on their molecular constituents (drugs/contrast agents), and quantify tissue functional changes (e.g., blood oxygenation and its concentration) within the image; in addition, manipulation with a needle is better visualized with PA. UW will work with GE Research to integrate spectroscopic PAUS into a high-end US scanner to create a clinical-grade PAUS system, and test whether it can improve interventional procedure guidance in general and, particularly, in ethanol (EA) ablation therapies of recurrent thyroid tumors. The prognosis for most people with thyroid cancer after primary treatment is very good, but the recurrence rate or persistence can be up to 30%. If recurrent cancer is confirmed, image-guided nonsurgical procedures such as EA or radio frequency ablation (RFA) are commonly used alternatives to more invasive procedures. Although US helps position EA and RFA needles, on-line imaging of the ablative area and confirmation of ablation remain difficult for US. When the recurrent nodule (especially the capillary network in it) is not entirely treated, the cancer will return with possible metastasis. We hypothesize here that real-time spectroscopic PAUS will improve the efficacy of ablation procedures and dramatically reduce procedure repetitions. If successful in this initial stage, the project will move to a clinical trial to both guide and validate ablative therapies and explore real-time spectroscopic PAUS for other interventional procedures. SA1 will integrate our unique laser and scanning fiber-optic delivery system with a clinical GE US scanner for real-time spectroscopic PAUS. Then, SA2 will develop real-time signal processing tools for motion correction and fluence compensation and imaging protocols for spectroscopic PAUS. SA3 will focus on optimizing the PAUS system using phantom and ex vivo studies. Finally, in SA4 the developed PAUS system will be used to test the clinical applicability of PAUS guidance with three in vivo models, including small animal studies of thyroid cancer, an animal model approximating human anatomy, and pilot measurements on human subjects.

抽象的该项目的目的是开发临床实时光谱光声/超声（PAUS）系统通过UW和GE研究之间的伙伴关系，用于介入程序的分子指导。最近，我们提出了一个用于PA成像的新的快速浏览概念。为了实践这个概念，我们首先开发了一个独特的，紧凑的，二极管的，可调的（700 -900 nm）激光器，以非常高（最高1000 Hz）重复速率和相对较低（〜1 MJ）的脉冲能量，以及依次的光纤递送系统将激光脉冲到成像探针中。除了美国B模式以及所有其他美国模式之外同时产生实时（50 Hz）光谱PA图像，首次合并用于实时PAUS成像。一个独特的功能是自动在线激光净值补偿和运动校正，在每个图像像素上都可以定量光吸收光谱。光谱可以根据它们的分子成分（药物/对比剂）确定不透明的物质，并进行量化图像中的组织功能变化（例如，血液氧合及其浓度）；此外，用针对针的操作可以更好地观察到PA。 UW将与GE Research合作，将光谱Paus整合到高端的美国扫描仪中，以创建一个临床级PAUS系统，并测试它是否可以改善一般的介入程序指南，并且特别是在复发性甲状腺肿瘤的乙醇（EA）消融疗法中。初次治疗后大多数甲状腺癌患者的预后非常好，但是复发率或持久性最多可以达到30％。如果确认复发性癌症，则图像引导的非手术程序此类由于EA或射频消融（RFA）是更具侵入性程序的常用替代方法。尽管美国有助于位置EA和RFA针，但在线成像，并确认对我们来说，消融仍然很困难。当复发结节（尤其是其中的毛细管网络）并非完全经过治疗，癌症将随着可能的转移而恢复。我们在这里假设实时光谱学 PAU将提高消融程序的功效，并大大减少程序重复。如果在这个初始阶段成功，该项目将进行临床试验，以指导和验证消融疗法并探索实时光谱PAU进行其他介入程序。 SA1将将我们独特的激光和扫描光纤传递系统与临床GE US扫描仪相结合实时光谱paus。然后，SA2将开发实时信号处理工具进行运动校正以及光谱PAUS的通量补偿和成像方案。 SA3将专注于优化使用幻影和体内研究的PAUS系统。最后，在SA4中，开发的PAUS系统将用于通过三个体内模型测试PAUS引导的临床适用性，包括甲状腺癌，一种近似人类解剖结构的动物模型，以及对人类受试者的试验测量。